Aleksandra Rachitskaya, MD, FASRS

0:56 Need for durable treatments in nAMD and DME

7:14 Highlights from clinical trials for faricimab

10:33 Post hoc analyses of faricimab clinical trials

16:24 Factors affecting retreatment decision

29:06 Choosing between faricimab and high-dose aflibercept

Videos

Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.

Achieving Superior Treatment Durability and Outcomes In Neovascular AMD and DME

0:52 Need for durable treatments in nAMD and DME

7:10 Highlights from clinical trials for faricimab

10:28 Post hoc analyses of faricimab clinical trials

16:19 Factors affecting retreatment decision

29:00 Choosing between faricimab and high-dose aflibercept

Aleksandra Rachitskaya, MD, FASRS

Articles